Eligible patients for part A of the trial must have unresectable, advanced or metastatic disease confirmed by histology or cytology. Patients with mixed histology may enroll if at least 50% of the ...

Your healthcare team might call them pancreatic neuroendocrine neoplasms (NENs). But neuroendocrine cancer and neuroendocrine neoplasm mean the same thing. There are different types of cancer that ...

Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older. The phase 3 CABINET trial showed improved progression-free ...

The approval for use in advanced neuroendocrine tumors is supported by data from the phase 3 CABINET trial (ClinicalTrials.gov Identifier: NCT03375320). The double-blind, placebo-controlled study ...

This tells them how quickly or slowly the cancer cells are growing. This is the grade. The stage of a neuroendocrine cancer tells you about its size and whether it has spread. Neuroendocrine cancers ...

Cabozantinib improves progression-free survival (PFS) in patients with advanced extrapancreatic neuroendocrine tumors and pancreatic neuroendocrine tumors compared with placebo. Cabozantinib ...

This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors ...

By comparing tumors uptake of three different tracers, the result indicated a high possibility of primary grade 2 pancreatic neuroendocrine neoplasm; then, we performed endoscopic ultrasound-guided ...

Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment of previously treated, progressive extrapancreatic or pancreatic ...

Neuroendocrine tumors, including small cell lung cancer and neuroendocrine prostate cancer, are very aggressive with high chances of spreading. However, many individuals develop resistance to few ...

MIAMI, FLORIDA (April 30, 2024) – Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of ...